Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Lundin, J
Kimby, E
Bjorkholm, M
Celsing, F
Hale, G
Hjalmar, V
Merup, M
Petrescu, A
Tullgren, O
Waldmann, H
Mellstedt, H
Osterborg, A
机构：
[1] Karolinska Inst, S-10401 Stockholm, Sweden
[2] Therapeut Antibody Ctr, Oxford, England
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：772A / 772A
页数：1
相关论文
共 50 条
  • [1] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Lundin, J
    Björkholm, M
    Celsing, F
    Hale, G
    Hjalmar, V
    Kimby, E
    Tullgren, O
    Waldman, H
    Mellstedt, H
    Österborg, A
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [2] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Mellstedt, H
    Österborg, A
    Lundin, J
    Björkholm, M
    Celsing, F
    Hagberg, H
    Hast, R
    Hjalmar, V
    Kimby, E
    Luthman, M
    Tullgren, O
    Werner, B
    BLOOD, 1998, 92 (10) : 490A - 490A
  • [3] A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901.
    Rai, KR
    Byrd, JC
    Peterson, BL
    Larson, RA
    BLOOD, 2002, 100 (11) : 205A - 206A
  • [4] Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
    L Alinari
    R Lapalombella
    L Andritsos
    R A Baiocchi
    T S Lin
    J C Byrd
    Oncogene, 2007, 26 : 3644 - 3653
  • [5] Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
    Alinari, L.
    Lapalombella, R.
    Andritsos, L.
    Baiocchi, R. A.
    Lin, T. S.
    Byrd, J. C.
    ONCOGENE, 2007, 26 (25) : 3644 - 3653
  • [6] Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Ravandi, F
    O'Brien, S
    Manero, GG
    Thomas, DA
    Browning, ML
    Keating, MJ
    BLOOD, 2005, 106 (11) : 831A - 831A
  • [7] Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia
    Lin, TS
    Flinn, IW
    Lucas, MS
    Porcu, P
    Sickler, J
    Moran, ME
    Lucas, DM
    Heerema, NA
    Grever, MR
    Byrd, JC
    LEUKEMIA, 2005, 19 (07) : 1207 - 1210
  • [8] Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia
    T S Lin
    I W Flinn
    M S Lucas
    P Porcu
    J Sickler
    M E Moran
    D M Lucas
    N A Heerema
    M R Grever
    J C Byrd
    Leukemia, 2005, 19 : 1207 - 1210
  • [9] Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study
    Dyer, MJS
    Buckby, E
    Fermahan, P
    Walewska, R
    Kennedy, B
    BLOOD, 2005, 106 (11) : 830A - 830A
  • [10] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
12345